Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans
Goya, María Eugenia; Xue, Feng; Sampedro-Torres-Quevedo, Cristina; Arnaouteli, Sofia; Riquelme-Dominguez, Lourdes; Romanowski, Andrés; Brydon, Jack; Ball, Kathryn L.; Stanley-Wall, Nicola R.; Doitsidou, Maria
(2020) Cell Reports, volume 30, issue 2, pp. 367 - 380.e7
(Article)
Abstract
How the gut microbiome affects Parkinson's disease remains unclear. Goya et al. show that the probiotic B. subtilis strain PXN21 inhibits and clears α-synuclein aggregation in a C. elegans model. The bacterium acts via metabolites and biofilm formation to activate protective pathways in the host, including DAF-16/FOXO and sphingolipid metabolism.
show less
Download/Full Text
Keywords: B. subtilis, biofilm, C. elegans, DAF-16/FOXO, dietary restriction, microbiota, Parkinson's disease, probiotics, sphingolipid metabolism, α-synuclein, General Biochemistry,Genetics and Molecular Biology
ISSN: 2211-1247
Publisher: Elsevier Saunders
Note: Funding Information: We thank Claire B?nard, Sebastian Greiss, Oliver Hobert, Anton Gartner, Luisa Cochella, Emanuel Busch, Diego Golombek, Ailish Tynan and Claudio Valverde for helpful discussions and feedback on the manuscript; EdinOmics and Tessa Moses for expert assistance; Viktoria Bajuszova for technical support; Francis Turner and Edinburgh Genomics for RNA-seq analysis; Jos? C. Riquelme, Crispin Jordan, and Ignacio Spiousas for input on statistical analysis; Ellen Nollen for the NL5901 strain; Life Science Editors for editing assistance; and Ms. Vickie Cunnane for her generous donation. Funding sources include EMBO ALTF 529-2017 and MSCA-IF 798650 to M.E.G.; Parkinson's UK, United Kingdom, project grant PRO-17-21 to M.D. and F.X.; BBSRC, United Kingdom, BB/P001335/1 grant to N.R.S.-W. and BB/R50614X/1 grant to K.L.B. which supports J.B.; and the Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund ISSF3 award to M.D. Some strains were provided by the CGC, funded by NIH Office of Research Infrastructure Programs (P40 OD010440), the Bacillus Genetic Stock Centre funded by the National Science Foundation (1756219), and the Gene Knockout Project at the Oklahoma Medical Research Foundation. The Wormlab was acquired with funding from the Muir Maxwell Epilepsy Centre. M.D. M.E.G. F.X. C.S.-T.-Q. and L.R.-D. designed, performed, and analyzed experiments with C. elegans; J.B. and K.L.B. designed, performed, and analyzed western blot experiments; N.R.S.-W. and S.A. designed, performed, and analyzed B. subtilis biofilm experiments and generated bacterial strains; A.R. contributed with the RNA-seq and qRT-PCR analysis; and M.D. provided oversight for the project and wrote the paper. All authors contributed to editing the manuscript. The authors declare no competing interests. Funding Information: We thank Claire Bénard, Sebastian Greiss, Oliver Hobert, Anton Gartner, Luisa Cochella, Emanuel Busch, Diego Golombek, Ailish Tynan and Claudio Valverde for helpful discussions and feedback on the manuscript; EdinOmics and Tessa Moses for expert assistance; Viktoria Bajuszova for technical support; Francis Turner and Edinburgh Genomics for RNA-seq analysis; José C. Riquelme, Crispin Jordan, and Ignacio Spiousas for input on statistical analysis; Ellen Nollen for the NL5901 strain; Life Science Editors for editing assistance; and Ms. Vickie Cunnane for her generous donation. Funding sources include EMBO ALTF 529-2017 and MSCA-IF 798650 to M.E.G.; Parkinson's UK , United Kingdom, project grant PRO-17-21 to M.D. and F.X.; BBSRC , United Kingdom, BB/P001335/1 grant to N.R.S.-W. and BB/R50614X/1 grant to K.L.B. which supports J.B.; and the Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund ISSF3 award to M.D. Some strains were provided by the CGC , funded by NIH Office of Research Infrastructure Programs ( P40 OD010440 ), the Bacillus Genetic Stock Centre funded by the National Science Foundation ( 1756219 ), and the Gene Knockout Project at the Oklahoma Medical Research Foundation . The Wormlab was acquired with funding from the Muir Maxwell Epilepsy Centre. Publisher Copyright: © 2019 The Author(s)
(Peer reviewed)
